Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
Shiv K. Gupta(Mayo Clinic), Jann N. Sarkaria(Mayo Clinic in Arizona), Katrina K. Bakken(Mayo Clinic in Arizona), Joel M. Reid(Children's Hospital of Philadelphia), Sani H. Kizilbash(Mayo Clinic), Jeanette E. Eckel‐Passow(Mayo Clinic in Florida), Jenny L. Pokorny(Mayo Clinic), Ling Cen(The Ohio State University), Brett L. Carlson(University of California, San Francisco), Felix Boakye‐Agyeman(Mayo Clinic), Erik P. Sulman(NYU Langone Health), Robert B. Jenkins(Dartmouth–Hitchcock Medical Center), Paul A. Decker(University of California, San Francisco), Karla V. Ballman(Mayo Clinic in Arizona), Ann C. Mladek(Mayo Clinic), Mark A. Schroeder(MACOM (United States)), Roeland Verhaak(Broad Institute), Gaspar J. Kitange(Hormel (United States)), Gobinda Sarkar(Mayo Clinic)
Cited by 122
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k